ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Genetics
Bioinformatics and experimental analysis revealed the cancer-promoting role of NCAPG2 in epithelial ovarian cancer
Xiabing Li 1,2
Yaping Wang 1,2
Luyao Kang 1,2
Hai Zhu 1,2
Qing Liu 1,2
Hongyu Li 1,2,3
1. Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2. Key Laboratory of Applied Chemistry, School of Chemistry, Zhengzhou University, Zhengzhou, China, Henan Province, 450001
3. The International Joint Laboratory of Ovarian Malignant Tumor,, zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Introduction: Ovarian cancer (OC) is one of the most common gynecological malignancies with an extremely poor prognosis. Among them, epithelial ovarian cancer (EOC) is the most common histological type and exhibits more aggressive behavior. Non-SMC condensin II complex subunit G2 (NCAPG2) is crucial for the execution of chromosomal mitosis and the promotion of tumorigenesis, but its role in the progression of EOC remains unclear. Method: In this study, we first analyzed the expression of NCAPG2 in EOC using data from the cancer genome atlas program (TCGA) database, Genotype-Tissue Expression (GTEx) project, and the Gene Expression Omnibus (GEO) dataset (GSE9891). Subsequently, bioinformatics tools were used to explore the expression of NCAPG2 in EOC and its related functions. In addition, we also evaluated the role of NCAPG2 in DNA damage repair, chemotherapy resistance, immune cell infiltration, and immunotherapy response. Finally, its expression and function have been verified through clinical samples and in vitro experiments. Result: Analyses of databases revealed that NCAPG2 is significantly overexpressed in EOC tissues and cells. NCAPG2 plays a role in DNA damage repair, chemotherapy resistance, immune cell infiltration, and immunotherapy response. More importantly, knockdown of NCAPG2 by siRNA can inhibit the proliferation, migration, and invasion abilities of EOC cells A2780 and OVCAR3 in vitro through the epithelial-mesenchymal transition (EMT) signaling pathway. Clinical specimens have confirmed that NCAPG2 is highly expressed in EOC tissues and is closely related to the clinical stage. Conclusion: High expression of NCAPG2 can promote the progression of EOC and may serve as a potential novel therapeutic target for EOC.
Summary
Keywords
Bioinformatics analysis, Cell metastasis, cellproliferation, epithelial ovarian cancer, NCAPG2
Received
12 February 2025
Accepted
20 February 2026
Copyright
© 2026 Li, Wang, Kang, Zhu, Liu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hongyu Li
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.